Molecular and Cellular Mechanism in the course of Immunotherapy with a Phleum Pratense Oral Lyophilisate

Trial Profile

Molecular and Cellular Mechanism in the course of Immunotherapy with a Phleum Pratense Oral Lyophilisate

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Feb 2017

At a glance

  • Drugs Timothy grass pollen allergen extract (Grastek) (Primary)
  • Indications Allergic rhinitis; Allergic rhinoconjunctivitis; Grass pollen hypersensitivity
  • Focus Biomarker; Pharmacodynamics
  • Sponsors ALK-Abello
  • Most Recent Events

    • 04 Feb 2017 Last checked against ClinicalTrials.gov record.
    • 05 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 23 Feb 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top